BR112017000584B1 - Compostos heteroarila, composição farmacêutica e seus usos como inibidores da aldosterona sintase - Google Patents

Compostos heteroarila, composição farmacêutica e seus usos como inibidores da aldosterona sintase Download PDF

Info

Publication number
BR112017000584B1
BR112017000584B1 BR112017000584-0A BR112017000584A BR112017000584B1 BR 112017000584 B1 BR112017000584 B1 BR 112017000584B1 BR 112017000584 A BR112017000584 A BR 112017000584A BR 112017000584 B1 BR112017000584 B1 BR 112017000584B1
Authority
BR
Brazil
Prior art keywords
compound
mmol
alkyl
compounds
3alkyl
Prior art date
Application number
BR112017000584-0A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112017000584A2 (pt
Inventor
Jennifer Burke
Derek Cogan
John Lord
Daniel Richard Marshall
Bryan P. Mckibben
Maolin Yu
Yunlong Zhang
Matthew A. Cerny
Lee Fader
Kosea S. Frederick
Simon Surprenant
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of BR112017000584A2 publication Critical patent/BR112017000584A2/pt
Publication of BR112017000584B1 publication Critical patent/BR112017000584B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
BR112017000584-0A 2014-07-24 2015-07-23 Compostos heteroarila, composição farmacêutica e seus usos como inibidores da aldosterona sintase BR112017000584B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462028556P 2014-07-24 2014-07-24
US62/028,556 2014-07-24
PCT/US2015/041648 WO2016014736A1 (en) 2014-07-24 2015-07-23 Aldosterone synthase inhibitors

Publications (2)

Publication Number Publication Date
BR112017000584A2 BR112017000584A2 (pt) 2017-11-07
BR112017000584B1 true BR112017000584B1 (pt) 2022-07-26

Family

ID=53761616

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017000584-0A BR112017000584B1 (pt) 2014-07-24 2015-07-23 Compostos heteroarila, composição farmacêutica e seus usos como inibidores da aldosterona sintase

Country Status (34)

Country Link
US (1) US9334285B2 (ja)
EP (1) EP3172212B1 (ja)
JP (1) JP6250862B2 (ja)
KR (1) KR102378648B1 (ja)
CN (1) CN106488921B (ja)
AP (1) AP2016009616A0 (ja)
AR (1) AR101290A1 (ja)
AU (1) AU2015292632B2 (ja)
BR (1) BR112017000584B1 (ja)
CA (1) CA2956118C (ja)
CL (1) CL2017000040A1 (ja)
CO (1) CO2017000443A2 (ja)
CY (1) CY1121063T1 (ja)
DK (1) DK3172212T3 (ja)
EA (1) EA031105B1 (ja)
ES (1) ES2684050T3 (ja)
HR (1) HRP20181441T1 (ja)
HU (1) HUE039981T2 (ja)
IL (1) IL249665B (ja)
LT (1) LT3172212T (ja)
MX (1) MX368093B (ja)
MY (1) MY191352A (ja)
NZ (1) NZ727188A (ja)
PE (1) PE20170294A1 (ja)
PH (1) PH12017500089A1 (ja)
PL (1) PL3172212T3 (ja)
PT (1) PT3172212T (ja)
RS (1) RS57570B1 (ja)
SG (1) SG11201700595RA (ja)
SI (1) SI3172212T1 (ja)
TW (1) TWI600658B (ja)
UA (1) UA118801C2 (ja)
UY (1) UY36228A (ja)
WO (1) WO2016014736A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2724555T3 (es) * 2014-10-15 2019-09-12 Boehringer Ingelheim Int Inhibidores de la aldosterona sintasa
EP3227300B1 (en) * 2014-12-02 2019-06-19 Boehringer Ingelheim International GmbH Aldosterone synthase inhibitors
JP6914974B2 (ja) 2016-06-28 2021-08-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 腎疾患、心血管疾患、および線維性障害の治療に有用な二環式イミダゾール誘導体
SG10201610038SA (en) * 2016-07-29 2017-12-28 Apple Inc Systems and methods for management of asymmetrical multi-tapped battery packs
EP3962903A1 (en) 2019-05-01 2022-03-09 Boehringer Ingelheim International GmbH (r)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate
WO2023114170A1 (en) 2021-12-14 2023-06-22 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors for treating chronic kidney disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100703068B1 (ko) * 2003-12-30 2007-04-05 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
BRPI0709678A2 (pt) * 2006-03-29 2011-07-19 Novartis Ag compostos orgánicos
TW200808813A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TWI577671B (zh) * 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
US8912341B2 (en) * 2013-01-16 2014-12-16 Northwestern University Enantioselective N-heterocyclic carbene-catalyzed annulation reactions with imidazolidinones

Also Published As

Publication number Publication date
UA118801C2 (uk) 2019-03-11
RS57570B1 (sr) 2018-10-31
CL2017000040A1 (es) 2017-07-07
CA2956118A1 (en) 2016-01-28
LT3172212T (lt) 2018-08-27
JP2017521466A (ja) 2017-08-03
CO2017000443A2 (es) 2017-04-10
TWI600658B (zh) 2017-10-01
EP3172212A1 (en) 2017-05-31
WO2016014736A1 (en) 2016-01-28
BR112017000584A2 (pt) 2017-11-07
EP3172212B1 (en) 2018-06-13
KR20170032459A (ko) 2017-03-22
CA2956118C (en) 2022-11-15
IL249665A0 (en) 2017-02-28
PH12017500089B1 (en) 2017-05-22
CN106488921A (zh) 2017-03-08
AP2016009616A0 (en) 2016-12-31
SI3172212T1 (sl) 2018-10-30
EA201790253A1 (ru) 2017-07-31
DK3172212T3 (en) 2018-08-27
AU2015292632A1 (en) 2016-12-22
MX2017000929A (es) 2017-05-04
PH12017500089A1 (en) 2017-05-22
AU2015292632B2 (en) 2019-11-21
CY1121063T1 (el) 2019-12-11
EA031105B1 (ru) 2018-11-30
TW201619165A (zh) 2016-06-01
JP6250862B2 (ja) 2017-12-20
KR102378648B1 (ko) 2022-03-28
HRP20181441T1 (hr) 2018-11-02
IL249665B (en) 2019-08-29
ES2684050T3 (es) 2018-10-01
HUE039981T2 (hu) 2019-02-28
US20160024105A1 (en) 2016-01-28
UY36228A (es) 2016-01-29
PL3172212T3 (pl) 2018-11-30
PT3172212T (pt) 2018-10-08
AR101290A1 (es) 2016-12-07
MX368093B (es) 2019-09-19
MY191352A (en) 2022-06-18
US9334285B2 (en) 2016-05-10
CN106488921B (zh) 2019-03-15
NZ727188A (en) 2020-01-31
SG11201700595RA (en) 2017-02-27
PE20170294A1 (es) 2017-04-12

Similar Documents

Publication Publication Date Title
BR112017000584B1 (pt) Compostos heteroarila, composição farmacêutica e seus usos como inibidores da aldosterona sintase
EP2683710B1 (en) Soluble guanylate cyclase activators
JP5143916B2 (ja) 新規2環性複素環化合物
KR102240158B1 (ko) 사이클로알킬산 유도체, 그의 제조 방법, 및 그의 약학적 용도
EP3250569B1 (en) Aldosterone synthase inhibitors
CA2964754C (en) Aldosterone synthase inhibitors
JP6585718B2 (ja) 抗ヒスタミン剤としての新規ベンゾイミダゾール誘導体
JP6914974B2 (ja) 腎疾患、心血管疾患、および線維性障害の治療に有用な二環式イミダゾール誘導体
JP5667934B2 (ja) 新規2環性複素環化合物からなる医薬
BR112017005859B1 (pt) Inibidores de aldosterona sintase, seus usos e sais farmaceuticamente aceitáveis e composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/07/2015, OBSERVADAS AS CONDICOES LEGAIS